Photodynamic Therapy (PDT): Mechanism, Clinical Applications and Patient Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Photodynamic therapy (PDT) is a minimally invasive, tissue-selective cancer treatment and medical procedure that utilises the interaction of three essential components to produce cell death: a photosensitising agent (a light-activated drug), a specific wavelength of activating light, and molecular oxygen dissolved in the target tissue. In the absence of any one component, no therapeutic effect occurs — this selectivity is a fundamental safety advantage of PDT over conventional surgery or radiotherapy.

The photochemical mechanism proceeds in two pathways: Type I reaction generates free radicals and superoxide anions through direct electron transfer from the excited photosensitiser to biomolecules. Type II reaction (dominant for most clinical photosensitisers) involves energy transfer from the excited triplet-state photosensitiser to ground-state molecular oxygen, generating singlet oxygen (¹O₂) — a highly reactive oxygen species that oxidises proteins, lipids, and nucleic acids within milliseconds, causing direct cell death by apoptosis or necrosis, endothelial damage to tumour vasculature, and inflammatory immune responses.

PDT was first described clinically by Dougherty et al. in 1978 using haematoporphyrin derivative (HpD) for bladder cancer. Modern clinical practice uses second- and third-generation photosensitisers with improved selectivity, shorter skin photosensitivity periods, and better light absorption characteristics. The principal photosensitisers in current clinical use include:

• 5-aminolevulinic acid (ALA) — A prodrug that is converted intracellularly to protoporphyrin IX (PpIX), which preferentially accumulates in rapidly proliferating abnormal keratinocytes. Topical formulations include 10% ALA solution (Levulan Kerastick, FDA-approved for actinic keratosis) and 5-ALA 78 mg/g gel (Ameluz, EMA-approved).
• Methyl aminolevulinate (MAL, Metvix) — A methyl ester of ALA with greater lipophilicity and selectivity, approved in the EU and UK for actinic keratosis, Bowen's disease, and superficial or nodular basal cell carcinoma.
• Verteporfin (Visudyne) — A benzoporphyrin derivative monoacid ring A, administered intravenously for photodynamic treatment of choroidal neovascularisation in age-related macular degeneration (AMD).

PDT is approved by the FDA, EMA, and endorsed by NICE for a range of dermatological and oncological indications, with ongoing clinical development for new applications.

PDT is approved and clinically evidence-based for the following conditions, with emerging applications expanding the scope:

• Actinic keratosis (AK) — The primary and best-established dermatological indication. AK (solar keratosis) represents intraepidermal dysplasia caused by chronic ultraviolet exposure and carries a 0.1–10% annual risk of progression to squamous cell carcinoma. MAL-PDT and ALA-PDT achieve complete clearance rates of 70–90% per lesion and 35–60% full-field response for field cancerisation. NICE Technology Appraisal TA155 (2006) recommends MAL-PDT as a cost-effective treatment option for non-hyperkeratotic AK on the face and scalp.
• Bowen's disease (squamous cell carcinoma in situ) — MAL-PDT achieves complete response rates of 80–93% at 3 months, comparable to cryotherapy and 5-fluorouracil, with significantly superior cosmetic outcomes. NICE TA155 includes Bowen's disease as a PDT indication.
• Superficial basal cell carcinoma (sBCC) — MAL-PDT achieves complete response rates of 83–97% for superficial BCC lesions, with 5-year sustained response rates of approximately 76–87%. NICE Technology Appraisal TA163 (2006) recommends MAL-PDT as the preferred treatment for superficial BCC where surgery is unsuitable or where cosmetic outcome is a priority (e.g., face, scalp, lower legs). PDT is not recommended for nodular or infiltrative BCC as lesion thickness exceeds the penetration depth of activating light.
• Neovascular (wet) age-related macular degeneration (AMD) — Verteporfin PDT (Visudyne) administered intravenously is activated by 689 nm diode laser light directed at the choroidal neovascular membrane, selectively closing the abnormal vessels without damaging the overlying neurosensory retina. Validated by the landmark TAP (Treatment of AMD with Photodynamic therapy) trial and the ANCHOR trial comparing verteporfin PDT against ranibizumab. Largely superseded by intravitreal anti-VEGF therapy (ranibizumab, aflibercept) for most neovascular AMD patients, but still used for specific subtypes (polypoidal choroidal vasculopathy).
• Early-stage prostate cancer (WST11/TOOKAD) — Vascular-targeted PDT (VTP) using padeliporfin (WST11/TOOKAD Soluble) is a focal therapy for low-risk, localised prostate cancer. Activated by 753 nm laser delivered via transperineal needles under ultrasound guidance. Approved in Europe as a treatment option for low-risk prostate cancer (PCM301 trial).
• Early-stage oesophageal and lung cancer — Porfimer sodium (Photofrin) PDT is FDA-approved for endobronchial NSCLC and early-stage oesophageal cancer obstruction palliation. Delivered via endoscope or bronchoscope.
• Acne vulgaris — Low-dose ALA-PDT reduces Propionibacterium acnes colonisation and sebaceous gland activity, with clinical benefit in moderate-to-severe acne refractory to topical treatments.

PDT is a highly targeted procedure with eligibility determined by diagnosis, lesion characteristics, and individual patient factors:

• Dermatological PDT (AK, Bowen's, sBCC) — ideal candidates: Patients with multiple or large-area AK lesions (field cancerisation) unsuitable for individual cryotherapy sessions; AK or Bowen's disease on the face, scalp, or lower legs where superior cosmetic outcomes are desired; superficial BCC in locations where surgical excision would produce poor cosmetic results or where the patient declines surgery; immunocompromised patients (transplant recipients, HIV) with extensive field cancerisation who require repeated treatment over many years.
• Lesion suitability — PDT is effective for superficial lesions only. Actinic keratoses must be non-hyperkeratotic (or pre-treated with gentle curettage to remove scale and improve photosensitiser penetration). BCC must be superficial type (tumour thickness <2 mm); nodular BCC (>2 mm depth) and infiltrative or morphoeic BCC are not suitable as activating light cannot adequately penetrate the full tumour depth.
• AMD eligibility (verteporfin PDT): Classic or predominantly classic subfoveal choroidal neovascularisation (CNV) in patients with visual acuity of 6/60 or better. Largely replaced by anti-VEGF therapy; verteporfin PDT remains most relevant for polypoidal choroidal vasculopathy (PCV) and patients unsuitable for intravitreal injection.
• Contraindications: Porphyria (all types) — absolute contraindication to ALA/MAL-PDT as pre-existing porphyrin metabolism disorders cause severe phototoxic reactions. Known photosensitising medications (St John's wort, tetracyclines, phenothiazines, thiazide diuretics, fluoroquinolones) that amplify photosensitivity. Pregnancy and breastfeeding — PDT is not recommended during pregnancy due to limited safety data. Allergy to the photosensitiser agent.
• Special considerations: Patients with Fitzpatrick skin types IV–VI may experience more pronounced post-inflammatory hyperpigmentation. Patients on anticoagulants should be informed of small bruising risk from any curettage pre-treatment. Patients who live alone may need assistance during the 24–48 hour sun-avoidance period post-treatment.

Several distinct PDT protocols are used depending on the indication, photosensitiser, and light source:

• Conventional MAL-PDT (Metvix) protocol: MAL cream 160 mg/g is applied to the lesion (and a 5–10 mm margin) after gentle curettage to remove scale and crust, then occluded under a plastic film dressing for 3 hours in a dark environment to allow protoporphyrin IX (PpIX) accumulation. Activation is then performed using a narrow-band red light source (630 nm, CureLight or Aktilite CL128) delivering 37 J/cm². A second treatment is performed 7 days later. Lesion clearance is assessed at 3 months.
• ALA-PDT (Levulan / Ameluz) protocol: 5-ALA gel is applied topically for 3 hours under occlusion, then activated with red or blue light (depending on the formulation; BF-RhodoLED 630 nm lamp for Ameluz). Ameluz in combination with BF-RhodoLED lamp is FDA-approved for AK and has demonstrated superior field clearance compared to MAL/conventional light in head-to-head trials.
• Daylight PDT: An innovative modification of conventional PDT where the photosensitiser (MAL or nanoemulsion ALA gel) is applied after sunscreen, and natural daylight serves as the activating light source during a 2-hour outdoor period. No dedicated light source is required, making daylight PDT suitable for home-based or outpatient field treatment of AK. Multiple randomised trials demonstrate non-inferiority to conventional red-light MAL-PDT for AK clearance, with significantly less procedural pain. Optimal in spring and summer months when ambient light intensity exceeds 10,000 lux.
• Verteporfin PDT (Visudyne) protocol for AMD: Verteporfin 6 mg/m² is administered intravenously over 10 minutes. After 15 minutes (to allow drug distribution and uptake by abnormal choroidal vessels), 689 nm laser light (50 J/cm², 600 mW/cm²) is applied to the area of CNV for 83 seconds via slit lamp delivery. The procedure is repeated every 3 months as needed based on OCT and fluorescein angiography assessment.
• Vascular-targeted PDT (WST11/TOOKAD) for prostate cancer: Padeliporfin is administered intravenously. Twelve transperineal optical fibres are inserted under ultrasound and MRI guidance (TRUS-guided), targeting the affected prostate lobe. 753 nm laser light is delivered interstitially for 22.5 minutes, ablating the vascular supply to the target zone. Performed under general anaesthesia as a day-case procedure. Preserves surrounding urethral, sphincter, and neurovascular bundle structures.
• Fluorescence-guided surgery (5-ALA, Gliolan): Oral 5-ALA taken 3 hours before surgery causes PpIX accumulation in high-grade glioma cells, which fluoresce pink-red under violet-blue surgical microscope illumination (375–440 nm), enabling real-time intraoperative demarcation of tumour margins during brain tumour resection.

PDT offers a distinctive combination of clinical efficacy and patient-centred advantages that position it favourably against conventional treatments for its approved indications:

• Superior cosmetic outcomes for dermatological lesions — Systematic reviews and randomised trials consistently demonstrate that MAL-PDT produces significantly better cosmetic results than cryotherapy or 5-fluorouracil cream for AK, Bowen's disease, and superficial BCC. PDT selectively destroys abnormal keratinocytes while preserving dermal collagen and appendageal structures, healing with minimal scarring, pigmentation change, or textural alteration — critically important for facial lesions.
• Field treatment capability — PDT can treat large areas of field cancerisation (multiple contiguous AK lesions across a sun-damaged area) in a single session, which is impractical with lesion-by-lesion cryotherapy or surgical excision. This is particularly valuable in chronically immunosuppressed patients (e.g., organ transplant recipients) with extensive photodamage.
• No systemic toxicity — Topical photosensitisers (ALA, MAL) remain local to the application site, producing no systemic side-effects. The brief cutaneous photosensitivity window resolves within 24–48 hours of topical treatment — far shorter than the 4–6 week systemic photosensitivity produced by first-generation photosensitisers (porfimer sodium/Photofrin).
• Repeatability — PDT can be repeated in the same area as needed without accumulating toxicity, unlike radiotherapy which has lifetime dose limits. This is essential for managing the chronic nature of AK field cancerisation, where new lesions continue to emerge from photodamaged skin over years.
• AMD: vision preservation — In the TAP trial, verteporfin PDT reduced the risk of moderate vision loss (≥3 lines on ETDRS chart) by 10–15% at 24 months compared to placebo in classic CNV. In specific AMD subtypes such as polypoidal choroidal vasculopathy (PCV), combination verteporfin PDT plus anti-VEGF (ranibizumab) shows superior polyp regression compared to anti-VEGF monotherapy (EVEREST II trial).
• Focal prostate treatment: functional preservation — WST11 VTP in low-risk prostate cancer achieves significantly higher negative re-biopsy rates compared to active surveillance at 24 months (49% vs 14%, PCM301 trial), while preserving urinary continence and erectile function in >85% of patients — outcomes superior to radical prostatectomy or radiotherapy.

PDT is well-tolerated with predictable side-effects that are generally manageable and self-limiting:

• Phototoxic skin reactions — After topical PDT, treated areas are intensely photosensitive for 24–48 hours. Inadvertent sun or strong artificial light exposure during this window causes severe erythema, oedema, and blistering. Patients must strictly avoid sunlight and remain indoors or use opaque clothing covering treated areas for 48 hours post-treatment. This is the most critical patient safety precaution for conventional (non-daylight) PDT.
• Procedural pain during light illumination — Pain and burning sensation during the red-light illumination phase is common and can be severe, particularly for scalp AK lesions where pain scores average 5–7 on a 10-point visual analogue scale. Management strategies include: topical anaesthesia (EMLA cream applied 1 hour before illumination), cold air (Cryo 6) during illumination, reduced light irradiance with prolonged exposure time, fanning, and verbal re-assurance. Oral analgesics (ibuprofen 400 mg or co-codamol 30/500) are prescribed 30–60 minutes before treatment. Daylight PDT is substantially less painful due to lower illumination intensity, representing a major patient comfort advantage.
• Local inflammatory reaction — Expected and therapeutic: erythema, oedema, crusting, and exudation of treated lesions in the days following PDT reflects the inflammatory cascade necessary for complete lesion clearance. These resolve within 1–3 weeks. Severe reactions resembling an acute burn occasionally occur; topical corticosteroids, antiseptic dressings, or short courses of systemic antibiotics for secondary infection may be required.
• Post-inflammatory hyperpigmentation — More common in darker skin phototypes (Fitzpatrick IV–VI), temporary hyperpigmentation may persist for several months post-PDT. Sunscreen use reduces this risk. Post-inflammatory hypopigmentation is rare.
• Verteporfin-specific risks — Intravenous verteporfin causes systemic photosensitivity for 48 hours, during which patients must avoid sunlight exposure to skin and eyes — not just treated skin. Back pain during infusion is a characteristic adverse effect of verteporfin, occurring in approximately 35% of patients. Severe visual acuity decrease within 1 week post-treatment (severe vision decrease) was reported in approximately 1% of patients in clinical trials.
• Incomplete response and recurrence — Clearance rates are high but not 100%. Residual or recurrent lesions occur in 10–25% of treated sites and require repeat PDT or alternative therapy (cryotherapy, surgery) at 3-month review.

Structured follow-up after PDT varies by indication, with assessment of treatment response and planning of further management:

• Dermatological PDT — 3-month review: All patients treated for AK, Bowen's disease, or superficial BCC are reviewed at 3 months post-treatment for clinical assessment of lesion clearance. Complete clearance is defined as complete clinical resolution of all treated lesions. Partial responders (≥50% lesion reduction) may benefit from a repeat PDT course. Non-responders (<50% reduction) should be biopsied to exclude invasive carcinoma and referred for alternative treatment (surgery, radiotherapy).
• Actinic keratosis long-term surveillance — AK is a chronic condition on a background of photodamaged skin. Even after complete clearance, new lesions emerge from surrounding field-damaged skin over months to years. Annual to biannual dermatology review for skin cancer surveillance is recommended. Patients should be educated on sun protection (SPF 50+ sunscreen, sun-protective clothing, avoidance of peak UV hours), vitamin D supplementation if indicated, and self-examination for new suspicious lesions.
• AMD follow-up after verteporfin PDT — OCT and fluorescein angiography (or OCT-angiography) are performed every 3 months. Evidence of CNV activity (subretinal fluid, intraretinal fluid, lesion growth) triggers retreatment with verteporfin PDT or addition of intravitreal anti-VEGF therapy. In the current era, most patients receiving verteporfin PDT for neovascular AMD are treated with combination verteporfin plus anti-VEGF to reduce retreatment burden.
• Prostate cancer follow-up after VTP — Multiparametric MRI and template prostate biopsy are performed at 12 months after WST11 VTP to assess histological response. PSA monitoring at 3-monthly intervals. A negative re-biopsy after VTP allows entry into an active surveillance protocol. PSA rise or positive biopsy at follow-up triggers discussion of salvage radical therapy (prostatectomy, radiotherapy) — importantly, VTP does not preclude subsequent radical treatment.
• Skin cancer general surveillance — Any patient treated for AK, Bowen's, or BCC has a significantly elevated lifetime risk of further skin cancers, including invasive squamous cell carcinoma and melanoma. Annual full-body skin check by a dermatologist or specialist nurse is recommended as part of a long-term skin cancer surveillance programme, alongside patient-led skin self-examination between appointments.

The cost of PDT varies significantly by indication, photosensitiser used, light source type, number of sessions required, and healthcare setting:

• Photosensitiser drug costs — MAL cream (Metvix): approximately £90–£130 per tube (UK wholesale), typically one to two tubes per treatment session. ALA gel (Ameluz, 78 mg/g): approximately £120–£180 per tube. Verteporfin (Visudyne): approximately £900–£1,400 per vial (UK, one vial per eye treatment session). Padeliporfin (TOOKAD Soluble): approximately €5,000–€8,000 per treatment course.
• Light source equipment — Dedicated PDT light delivery systems (Aktilite CL128, CureLight) cost approximately £2,000–£5,000 and are durable devices used across multiple patients, so per-session equipment cost is relatively low. Daylight PDT eliminates the light source cost entirely, as natural sunlight serves as the activating light.
• UK NHS coverage — MAL-PDT for AK and superficial BCC is NHS-funded in secondary care (dermatology outpatient departments) in England, Scotland, and Wales, endorsed by NICE TA155 and TA163. Verteporfin PDT for polypoidal choroidal vasculopathy may be funded on a case-by-case basis through NHS commissioning. WST11 VTP for prostate cancer was approved as an NHS England commercial access agreement from 2019.
• Private costs (UK) — Private ALA/MAL-PDT per session (covering a small treatment field, two applications): £600–£1,200. Full-face field PDT per session: £800–£1,500. Multiple sessions over 12 months for field cancerisation management: £2,000–£5,000 total. Verteporfin PDT per eye treatment session: £1,200–£2,500.
• International cost comparison — PDT for AK and BCC is available in India, Thailand, Germany, and Hungary at significantly lower cost. PDT in India at specialised dermatology or oncology centres costs approximately $200–$500 USD per session, representing 70–80% savings compared to UK private rates.
• Daylight PDT cost-effectiveness — Daylight PDT eliminates the dedicated light source requirement, can potentially be administered as a home-based or outpatient protocol, and requires shorter clinic time than conventional PDT — making it a significantly more cost-effective approach for management of extensive AK field cancerisation when ambient daylight conditions permit.

Effective alternatives exist for most PDT indications; choice depends on lesion type, location, number, patient preference, and cosmetic priority:

• Cryotherapy (liquid nitrogen) — The most widely used alternative to PDT for individual AK lesions and thin Bowen's disease. Advantages: rapid, cheap, available in primary care. Disadvantages: less effective for field cancerisation (treats lesions individually rather than field-wide), higher rates of scarring and hypopigmentation, significantly inferior cosmetic outcomes compared to PDT for facial lesions, and reduced efficacy on lower legs. Complete response rates for individual AK lesions: 75–85% at 3 months (comparable to PDT for individual lesions; inferior for field treatment).
• Topical 5-fluorouracil (5-FU, Efudix 5%) — Antimetabolite cream applied daily for 2–4 weeks to fields of AK. Effective for field cancerisation. Produces predictable but intense inflammatory reaction (erythema, crusting, ulceration) that patients often find more distressing than PDT. Slower course (weeks vs single session). Similar clearance rates to PDT for field AK over 12 months, with slightly inferior cosmetic outcomes. Cost-effective.
• Topical imiquimod (Zyclara 3.75%, Aldara 5%) — Toll-like receptor 7 agonist that activates innate and adaptive immune responses against AK and superficial BCC. Applied daily for 2–6 weeks (AK) or 6 weeks (sBCC). Complete clearance rates: 45–80% for AK, 70–80% for sBCC. Causes local inflammatory reactions (erythema, erosion, flu-like symptoms). Cost-effective; widely used in primary care. Alternative to PDT when clinic-based treatment is impractical.
• Ingenol mebutate (Picato) — Formerly used for AK but withdrawn from the European market in 2020 due to concerns about increased skin cancer risk in treated fields. No longer recommended.
• Surgical excision — Gold standard for nodular and infiltrative BCC (complete excision with histological margin assessment), invasive SCC, and any lesion where diagnostic uncertainty exists. Produces the highest cure rates for BCC (99% 5-year recurrence-free survival with Mohs micrographic surgery). Not suitable for field cancerisation; cosmetically inferior to PDT for large facial lesions.
• Intravitreal anti-VEGF therapy (for AMD) — Ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu) are the current first-line treatment for neovascular AMD, having largely replaced verteporfin PDT monotherapy due to superior visual acuity gains in head-to-head trials (ANCHOR, MARINA). Anti-VEGF requires repeat intravitreal injections every 1–3 months but produces greater mean visual acuity improvement than PDT monotherapy.
• External beam radiotherapy (for BCC) — Superficial X-ray therapy (SXT) or electron beam radiotherapy is an effective alternative to PDT for BCC in elderly patients unsuitable for surgery, or for large or recurrent lesions. Cure rates of 90–95% for primary BCC; not repeatable in the same field; may cause long-term radiation dermatitis.